Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC

Inclusion Criteria:

1. Has a diagnosis of HCC confirmed by radiology, histology, or cytology;

2. Barcelona Clinic Liver Cancer (BCLC) stage C with the presence of extrahepaticspread;

3. Has not received any previous systemic therapy for HCC (including chemotherapy,molecularly targeted therapy, immunotherapy);

4. Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs patients received onlyinclude marketed drugs but are not limited to HCC approval;

5. TACE was performed after the first PD-1/PD-L1 inhibitor/anti-angiogenic drugtreatment or before treatment (within 3 months);

6. Received at least 1 cycle of PD-1/PD-L1 inhibitor/anti-angiogenic drug combinationtherapy after TACE treatment;

7. Has repeated measurable intrahepatic lesions;

Exclusion Criteria:

1. Cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, and mixedhepatocellular/cholangiocarcinoma subtypes(confirmed by histology, or pathology) arenot eligible;

2. Unable to meet criteria of combination timeframe described above;

3. Child-Pugh C or PS > 2 or Severe hepatic encephalopathy